Gentis Overview
- Year Founded
-
2000
- Status
-
Out of Business
- Employees
-
7
- Latest Deal Type
-
Out of Business
Gentis General Information
Description
Provider of biomaterials-based products designed to treat the early-stage degeneration of the spine. The company's biomaterials-based product, DiscCell, is an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material that augments or replaces the diseased nucleus pulposus of the spinal disc, enabling patients to prevent a recurrence of back or leg pain at the treatment site.
Contact Information
Website
www.gentisinc.comCorporate Office
- 400 East Lancaster Avenue
- Suite 300
- Wayne, PA 19087
- United States
Corporate Office
- 400 East Lancaster Avenue
- Suite 300
- Wayne, PA 19087
- United States
Gentis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 01-Jun-2016 | Completed | Out of Business | |||
| 5. Secondary Transaction - Private | 01-Apr-2014 | Completed | Profitable | |||
| 4. Later Stage VC | 02-Feb-2014 | Completed | Profitable | |||
| 3. Later Stage VC | Completed | Profitable | ||||
| 2. Later Stage VC (Series B) | 19-Jul-2010 | $548K | $12.5M | Completed | Profitable | |
| 1. Later Stage VC (Series A) | 22-Jun-2007 | $12M | $12M | Completed | Profitable |
Gentis Patents
Gentis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20050112186-A1 | Nontoxic, biocompatible water in oil emulsion with organic phase of ethenically unsaturated monomers or oligomers that does not provoke an autoimmune or inflammatory response for reforming damaged or diseased intervertebral discs by noninvasive means | Active | 29-Oct-2003 | ||
| US-20070218124-A1 | Nontoxic, biocompatible water in oil emulsion with organic phase of ethenically unsaturated monomers or oligomers that does not provoke an autoimmune or inflammatory response for reforming damaged or diseased intervertebral discs by noninvasive means | Active | 29-Oct-2003 | ||
| US-20070248643-A1 | Nontoxic, biocompatible water in oil emulsion with organic phase of ethenically unsaturated monomers or oligomers that does not provoke an autoimmune or inflammatory response for reforming damaged or diseased intervertebral discs by noninvasive means | Active | 29-Oct-2003 | ||
| US-7537754-B2 | Nontoxic, biocompatible water in oil emulsion with organic phase of ethenically unsaturated monomers or oligomers that does not provoke an autoimmune or inflammatory response for reforming damaged or diseased intervertebral discs by noninvasive means | Inactive | 29-Oct-2003 | ||
| US-7651682-B2 | Nontoxic, biocompatible water in oil emulsion with organic phase of ethenically unsaturated monomers or oligomers that does not provoke an autoimmune or inflammatory response for reforming damaged or diseased intervertebral discs by noninvasive means | Inactive | 29-Oct-2003 | A61L27/26 |
Gentis Signals
Gentis FAQs
-
When was Gentis founded?
Gentis was founded in 2000.
-
Where is Gentis headquartered?
Gentis is headquartered in Wayne, PA.
-
What is the size of Gentis?
Gentis has 7 total employees.
-
What industry is Gentis in?
Gentis’s primary industry is Surgical Devices.
-
Is Gentis a private or public company?
Gentis is a Private company.
-
What is Gentis’s current revenue?
The current revenue for Gentis is .
-
How much funding has Gentis raised over time?
Gentis has raised $13.3M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process